GHRH (Growth Hormone-Releasing Hormone) + Larazotide Acetate stack
A research-context overview of stacking GHRH (Growth Hormone-Releasing Hormone) with Larazotide Acetate: the rationale, complementary benefits, side-effect overlap, and pharmacokinetic considerations. Educational only — never a recommendation.
Why this stack?
Pairing a Performance peptide like GHRH (Growth Hormone-Releasing Hormone) with a Recovery peptide like Larazotide Acetate is one of the most common stack archetypes in the research literature. The Performance compound drives the GH/IGF-1 axis or anabolic signaling; the Recovery compound shortens the soft-tissue and inflammation tax of training, letting the anabolic signal land on healthier tissue. The two work on independent pathways, so timing concerns are minimal — most researchers dose them on separate clocks.
GHRH (Growth Hormone-Releasing Hormone)
Native 44-aa hypothalamic GHRH; parent molecule of sermorelin, CJC-1295, and tesamorelin.
Key benefits
- ✓Pulsatile GH release
- ✓Preserves natural HPA axis
- ✓Reference comparator for analogs
Side effects to watch
- ⚠Flushing
- ⚠Headache
- ⚠Injection-site reactions
Larazotide Acetate
Tight-junction regulator developed for celiac disease; reduces intestinal permeability.
Key benefits
- ✓Tightens intestinal junctions
- ✓Reduces leaky-gut markers
- ✓Studied in celiac disease
Side effects to watch
- ⚠Headache
- ⚠Nausea
- ⚠Upper respiratory symptoms
Half-life considerations
Reference half-life data for one or both of these compounds is not in our table — see the individual peptide profiles for cited PK ranges.
Educational use only
This calculator is provided for research and educational purposes. Outputs are derived from the values you enter. Always verify your math and consult a licensed physician before acting on any result.